```
=> b reg
FILE 'REGISTRY' ENTERED AT 11:47:36 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 MAR 2009  HIGHEST RN 1115640-24-8
DICTIONARY FILE UPDATES:   4 MAR 2009  HIGHEST RN 1115640-24-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l11
L7      1216632 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES AND (46.150.18 OR
                46.156.30)/RID AND NR>=3
L9              STR
```




```
REP G1=(0-7) C
VAR G2=CB/HY
VAR G3=9/10/11/16/17/18
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2   9  15
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L11       106513 SEA FILE=REGISTRY SUB=L7 SSS FUL L9

100.0% PROCESSED  821728 ITERATIONS                      106513 ANSWERS
SEARCH TIME: 00.00.52



=> d que sta l15
L7      1216632 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES AND (46.150.18 OR
                46.156.30)/RID AND NR>=3
L9              STR
```




```
REP G1=(0-7) C
```

VAR G2=CB/HY
VAR G3=9/10/11/16/17/18
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 2 9 15
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L11 106513 SEA FILE=REGISTRY SUB=L7 SSS FUL L9
L12 STR



REP G1=(0-7) C
VAR G2=CB/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 2
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L13 STR



REP G1=(0-7) C
VAR G2=CB/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 2
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L15 6421 SEA FILE=REGISTRY SUB=L11 SSS FUL (L12 OR L13)

100.0% PROCESSED 106513 ITERATIONS 6421 ANSWERS
SEARCH TIME: 00.00.15

=> d que sta l31
L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US20060276650 /PN
L2 TRANSFER PLU=ON L1 1- RN : 49 TERMS
L3 49 SEA FILE=REGISTRY ABB=ON PLU=ON L2
L7 1216632 SEA FILE=REGISTRY ABB=ON PLU=ON N2C3/ES AND (46.150.18 OR 46.156.30)/RID AND NR>=3
L9 STR



REP G1=(0-7) C
VAR G2=CB/HY
VAR G3=9/10/11/16/17/18
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2   9 15
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L11   106513 SEA FILE=REGISTRY SUB=L7 SSS FUL L9
L12   STR



REP G1=(0-7) C
VAR G2=CB/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L13   STR



REP G1=(0-7) C
VAR G2=CB/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L15   6421 SEA FILE=REGISTRY SUB=L11 SSS FUL (L12 OR L13)
L16   29 SEA FILE=REGISTRY ABB=ON PLU=ON L15 AND L3
L17   6392 SEA FILE=REGISTRY ABB=ON PLU=ON L15 NOT L16
L28   STR



Cb @11 Hy @12

REP G1=(0-7) C
VAR G2=11/12
NODE ATTRIBUTES:
CONNECT IS M1 RC AT   4
CONNECT IS M1 RC AT   5
CONNECT IS M1 RC AT 11
CONNECT IS M1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L29   STR



Cb 11 Hy 12

REP G1=(0-7) C
VAR G2=CB/HY
NODE ATTRIBUTES:
CONNECT IS M1 RC AT   4
CONNECT IS M1 RC AT   5
CONNECT IS M1 RC AT 11
CONNECT IS M1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L31   1733 SEA FILE=REGISTRY SUB=L17 CSS FUL (L28 OR L29)

100.0% PROCESSED   6392 ITERATIONS   1733 ANSWERS
SEARCH TIME: 00.00.02

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:47:48 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

strictly prohibited.

FILE COVERS 1907 - 6 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 5 Mar 2009 (20090305/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l20 tot

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:841774 HCAPLUS
DN 141:332187
TI Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.
IN Schadt, Oliver; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 24 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE-----10315571	A1	20041014	2003DE-100015571	20030405
	AU--2004228119	A1	20041021	2004AU-000228119	20040308
	CA-----2521199	A1	20041021	2004CA-002521199	20040308
	WO--2004089888	A1	20041021	2004WO-EP0002352	20040308
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP-----1611094	A1	20060104	2004EP-000718288	20040308
	EP-----1611094	B1	20070620		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR--2004009160	A	20060502	2004BR-000009160	20040308
	CN-----1768053	A	20060503	2004CN-080008604	20040308
	JP--2006523626	T	20061019	2006JP-000504583	20040308
	AT------365161	T	20070715	2004AT-000718288	20040308
	ES-----2287707	T3	20071216	2004ES-000718288	20040308
	US-20060276650	A1	20061207	2005US-000551905	20051005 <--
PRAI	2003DE-100015571	A	20030405		
	2004WO-EP0002352	W	20040308		

OS MARPAT 141:332187
GI



I

AB Title compds. [I; R2, R4 = H, A, halo, cycloalkyl, CF3, NO2, cyano, OCF3, OA, NHA, NA2, NH2; R3, R6 = (CH2)nHet, (CH2)nAr; R1 = H, organic residue; A = alkyl, alkoxy, alkenyl, alkenyloxyalkyl; Het = (substituted) (unsatd.) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; Ar = (substituted) Ph; n = 0-5; X undefined], were claimed (no synthetic or biol. data).
IT **32701-89-6 1070643-43-4 1070643-44-5**
1070643-56-9 1070643-57-0 1070643-58-1
1070643-59-2 1070643-60-5 1070643-61-6
1070643-62-7 1070643-63-8 1070643-64-9
1070643-65-0 1070643-66-1 1070643-67-2
1070643-68-3 1070643-69-4 1070643-70-7
1070643-71-8 1070643-72-9 1070643-73-0

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1070643-74-1 1070643-75-2 1070643-76-3
1070643-77-4 1070643-78-5 1070643-79-6
1070643-80-9 1070643-81-0
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)
IT **32701-89-6**
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)
RN 32701-89-6 HCAPLUS
CN 1H-Pyrazole-4-acetic acid, 1-[1,1'-biphenyl]-4-yl-3-methyl-5-phenyl-, ethyl ester (CA INDEX NAME)



=> d bib abs hitstr l21 tot

L21 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 1971:449072 HCAPLUS
DN 75:49072
OREF 75:7749a,7752a
TI Antiphlogistic, analgesic, and antipyretic substituted pyrazole-4-acetic acid derivatives
IN Rainer, Georg; Riedel, Richard; Klemm, Kurt
PA Byk-Gulden Lomberg Chemische Fabrik G.m.b.H.
SO Ger. Offen., 44 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE-----1946370	A	19710422	1969DE-001946370	19690912
	DE-----1946370	B2	19781109		
	DE-----1946370	C3	19790726		
	CH------583707	A5	19770114	1973CH-000003460	19700828
	CH------587251	A5	19770429	1970CH-000012904	19700828
	GB-----1307005	A	19730214	1970GB-000043147	19700909
	NL------7013384	A	19710316	1970NL-000013384	19700910
	CA------959838	A1	19741224	1970CA-000092873	19700910
	SE------385212	B	19760614	1970SE-000012345	19700910
	ZA------7006215	A	19710527	1970ZA-000006215	19700911
	FR-----2070689	A5	19710917	1970FR-000033102	19700911
	FR-----2070689	A1	19710917		
	AT------304534	B	19730110	1970AT-000008261	19700911
	AT------313274	B	19740211	1972AT-000001884	19700911
	JP----51033906	B	19760922	1970JP-000079421	19700911
	JP----53039435	B	19781021	1974JP-000062988	19740605
	US-----4325962	A	19820420	1978US-000969872	19781215
PRAI	1969DE-001946370	A	19690912		
	1970US-000072233	A3	19700914		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R, R1, R2 = H, alkyl, allyl, cycloalkyl, and variously substituted phenyl and benzyl, R3 = H, Me) were prepared by the reaction of hydrazines RNHNH2 with dicarbonyl compds. R1CO(R2CO)CHCHR3CO2H (II) or by hydrolysis of esters, amides, nitriles, etc., of I. II were prepared by base-catalyzed condensation of 1,3-diketones with alkylbromoacetates. Forty examples were given and antiphlogistic and analgesic data reported.
IT **32701-89-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32701-89-6 HCAPLUS
CN 1H-Pyrazole-4-acetic acid, 1-[1,1'-biphenyl]-4-yl-3-methyl-5-phenyl-, ethyl ester (CA INDEX NAME)



=> d bib abs hitstr l39 tot

L39 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 1979:420496 HCAPLUS
DN 91:20496
OREF 91:3433a,3436a
TI 4-Pyrazoleacetic acid derivatives
IN Rainer, Georg
PA Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SO U.S., 21 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US-----4146721	A	19790327	1970US-000072233	19700914
	US-----4325962	A	19820420	1978US-000969872	19781215
PRAI	1969DE-001946370	A	19690912		
	1970US-000072233	A3	19700914		

OS MARPAT 91:20496
GI



I

AB Pyrazoleacetic acid derivs. I (R = CO2H, alkoxycarbonyl, CONH2; R1, R2 = optionally substituted Ph, furyl, thienyl, naphthyl; R3 = H, Ph, furyl) were prepared Thus, CH2Ac2 was treated with BrCH2CO2Et to give Ac2CHCH2CO2Et which was cyclized with PhNHNH2 to give I (R = CO2Et, R1 = Ph, R2 = R3 = Me), which was hydrolyzed to the acid. I had antiinflammatory and analgesic activity. Thus, I (R = CO2H, R1 = Ph, R2 = R3 = 2-furyl) had antiinflammatory ED50 in the UV erythema test of 1.5 mg/kg orally and then analgesic ED40 50 mg/kg orally.
IT **32701-90-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 32701-90-9 HCAPLUS
CN 1H-Pyrazole-4-acetic acid, 1-[1,1'-biphenyl]-4-yl-3-methyl-5-phenyl- (CA INDEX NAME)



RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of

L39 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 1971:449072 HCAPLUS
DN 75:49072
OREF 75:7749a,7752a
TI Antiphlogistic, analgesic, and antipyretic substituted pyrazole-4-acetic acid derivatives
IN Rainer, Georg; Riedel, Richard; Klemm, Kurt
PA Byk-Gulden Lomberg Chemische Fabrik G.m.b.H.
SO Ger. Offen., 44 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE-----1946370	A	19710422	1969DE-001946370	19690912
	DE-----1946370	B2	19781109		
	DE-----1946370	C3	19790726		
	CH------583707	A5	19770114	1973CH-000003460	19700828
	CH------587251	A5	19770429	1970CH-000012904	19700828
	GB-----1307005	A	19730214	1970GB-000043147	19700909
	NL-----7013384	A	19710316	1970NL-000013384	19700910
	CA-----959838	A1	19741224	1970CA-000092873	19700910
	SE------385212	B	19760614	1970SE-000012345	19700910
	ZA-----7006215	A	19710527	1970ZA-000006215	19700911
	FR-----2070689	A5	19710917	1970FR-000033102	19700911
	FR-----2070689	A1	19710917		
	AT-----304534	B	19730110	1970AT-000008261	19700911
	AT------313274	B	19740211	1972AT-000001884	19700911
	JP----51033906	B	19760922	1970JP-000079421	19700911
	JP----53039435	B	19781021	1974JP-000062988	19740605
	US-----4325962	A	19820420	1978US-000969872	19781215
PRAI	1969DE-001946370	A	19690912		
	1970US-000072233	A3	19700914		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R, R1, R2 = H, alkyl, allyl, cycloalkyl, and variously substituted phenyl and benzyl, R3 = H, Me) were prepared by the reaction of hydrazines RNHNH2 with dicarbonyl compds. R1CO(R2CO)CHCHR3CO2H (II) or by hydrolysis of esters, amides, nitriles, etc., of I. II were prepared by base-catalyzed condensation of 1,3-diketones with alkylbromoacetates. Forty examples were given and antiphlogistic and analgesic data reported.
IT **32701-90-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32701-90-9 HCAPLUS
CN 1H-Pyrazole-4-acetic acid, 1-[1,1'-biphenyl]-4-yl-3-methyl-5-phenyl- (CA INDEX NAME)



=> d bib abs hitrn fhitstr l35 tot

L35 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:340606 HCAPLUS
DN 144:390911
TI Preparation of 1-phenyl-1H-pyrazole derivatives as PDK-1/AKT signaling inhibitors for the treatment of cancer and restenosis
IN Chen, Ching-Shih
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20060079566	A1	20060413	2004US-000957925	20041004 <--
CA-----2566846	A1	20050519	2004CA-002566846	20041004 <--
WO--2005044130	A1	20050519	2004WO-US0032723	20041004 <--
WO--2005044130	A9	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1696907	A1	20060906	2004EP-000816902	20041004 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN-----1889949	A	20070103	2004CN-080036007	20041004 <--
JP--2007527408	T	20070927	2006JP-000534245	20041004 <--
IN---200601131	A	20070831	2006IN-000001131	20060403 <--
KR--2006108651	A	20061018	2006KR-000708622	20060503 <--
US-20080146815	A1	20080619	2007US-000864612	20070928
US-20080269309	A1	20081030	2008US-000118788	20080512 <--
PRAI 2003US-00508619P	P	20031003	<--	
2003US-00509814P	P	20031008	<--	
2004US-000957925	B1	20041004		
2004WO-US0032723	W	20041004		
2007US-000864612	A1	20070928		

OS CASREACT 144:390911; MARPAT 144:390911
GI



AB Title compds. I [wherein X = (halo)alkyl; Ar = Ph, biphenyl, phenanthrenyl, etc.; R = CN, CH2CN, SO2NH2, etc.] and metabolites or pharmaceutically acceptable salts thereof were prepared as phosphoinositide-dependent kinase-1 (PDK-1/AKT) inhibitors. For instance, condensation of Et trifluoroacetate with 2-acetylphenanthrene using NaH as base in THF (90% yield) followed by cyclization with 4-hydrazinobenzene-1-sulfonamide hydrochloride in refluxing ethanol (80% yield) gave II. This product showed great potency in inhibiting PDK-1

L35 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
kinase activity and PC-3 cell growth with IC50 values of 9 μM and 5 μM, resp. Therefore, the invented compds. are useful for the treatment and prevention of cancer and restenosis.
IT **882854-60-6P 882854-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylpyrazoles as PDK-1/AKT signaling inhibitors for treatment of cancer and restenosis)
IT **882854-60-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylpyrazoles as PDK-1/AKT signaling inhibitors for treatment of cancer and restenosis)
RN 882854-60-6 HCAPLUS
CN 2H-Tetrazole, 5-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (CA INDEX NAME)



L35 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:325402 HCAPLUS
DN 145:103666
TI Preparation of pyrazoles as cyclooxygenase inhibitors
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Aust. Pat. Appl., 68 pp.
CODEN: AUXXCM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI AU--2004200420	A1	20040930	2004AU-000200420	20040206 <--
PRAI 2003AU-000901100	A	20030311	<--	

OS MARPAT 145:103666
GI



AB The title compds. I [R1 = halo, CN, alkylcarbonyl, etc.; R2 = halo, CN, alkyl, etc.; R3 = H, alkyl; R4 = halo, CN, NO2, alkyl, etc.; or R3 and R4 may form 2,3-dihydrofuryl; R5 = OH and R6 = H in case of single bond between carbon atoms to which R5 and R6 are attached; or R5 and R6 do not exist in case of double bond; Y = CH and Z = N, Y = N and Z = CH, or Y = N and Z = N], useful for treating and/or preventing inflammatory conditions, various pains, collagen disease, autoimmune diseases, various immunity diseases, thrombosis, cancer or neurodegenerative diseases, were prepared Thus, treating a solution of 5-amino-2-methoxypyridine in 1N HCl with sodium nitrite and with tin (II) chloride dihydrate followed by addition of 4-(4,4-difluoro-3-oxobutanoyl)benzonitrile and acetic acid afforded 32% 5-(4-cyanophenyl)-3-difluoromethyl-1-(6-methoxy-3-pyridyl)-1H-pyrazole which showed IC50 of <0.01 μM against COX-1. Pharmaceutical composition comprising the compound I is disclosed.
IT **896133-46-3P 896133-62-3P 896133-67-8P**
896133-68-9P 896133-69-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoles as cyclooxygenase inhibitors)
IT **896133-46-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoles as cyclooxygenase inhibitors)
RN 896133-46-3 HCAPLUS
CN Pyridine, 2-methoxy-5-[1-[4-(1H-pyrrol-1-yl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



L35 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L35 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:34107 HCAPLUS
DN 142:102889
TI Phosphorescent organic electroluminescent devices
IN Yoshitake, Osamu; Miyazaki, Hiroshi; Suzaki, Daisuke; Yamada, Hiroshi
PA Nippon Steel Chemical Co., Ltd., Japan; Japan Hydrazine Company Inc.
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP--2005011804	A	20050113	2004JP-000155979	20040526 <--
PRAI 2003JP-000153194	A	20030529	<--	

OS MARPAT 142:102889
GI



I

AB The device comprises, successively from the bottom, a substrate, an anode, organic layers including a light-emitting layer, and a cathode, wherein the light-emitting layer contains a dopant and a compound bearing 2-4 pyrazole substituents I [Ar4-6 = H, (substituted) aromatic hydrocarbyl, aromatic heterocycle; at least one of Ar4-6 ≠ H] as a host. The device durably provides high luminance light at high emission efficiency.
IT **53148-57-5P 819078-34-7P 819078-35-8P**
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(host in emitting layer; in phosphorescent electroluminescent device)
IT **53148-57-5P**
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(host in emitting layer; in phosphorescent electroluminescent device)
RN 53148-57-5 HCAPLUS
CN 1H-Pyrazole, 1,1'-([1,1'-biphenyl]-4,4'-diyl)bis[3,5-diphenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L35 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1018637 HCAPLUS
DN 142:13468
TI Pyrazoles, their charge transporting materials, and organic electroluminescent devices using them
IN Sato, Itsuki; Yoneyama, Tomio; Sato, Hideki
PA Mitsubishi Chemical Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP--2004331588	A	20041125	2003JP-000130432	20030508 <--
PRAI 2003JP-000130432		20030508	<--	

OS MARPAT 142:13468
GI



I

AB The pyrazoles are I [X = C:, N; Y, Z = CR3:, N:, NR4; R3, R4 = H, monovalent substituent; one of R1 and R2 = aromatic hydrocarbyl, aromatic heterocyclyl; the other of R1 and R2 = H, C1-5 alkyl; ≥1 of R1-R4 = monovalent electron-withdrawing group showing Hammet constant (σp) 0.00 < σp < 0.90, aromatic heterocyclyl, or monovalent group substituted with the aforementioned electron-withdrawing group or aromatic heterocycle; A = n-valent linkage containing ≥1 groups chosen from CO, SO2, and aromatic heterocyclylene, or substituted with the aforementioned electron-withdrawing group and/or aromatic heterocycle; n = 1-4]. Organic electroluminescent devices having hole blocking layers containing the pyrazoles show high luminescence efficiency. Thus, 2,5-bis[4-(3,5-diphenylpyrazolyl)phenyl]-1,3,4-oxadiazole was manufactured and its ionization potential was measured.
IT **796884-21-4P**
RL: DEV (Device component use); IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(manufacture of pyrazoles as charge transporting materials for organic electroluminescent devices)
IT **796884-21-4P**
RL: DEV (Device component use); IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(manufacture of pyrazoles as charge transporting materials for organic electroluminescent devices)
RN 796884-21-4 HCAPLUS
CN 1,3,4-Oxadiazole, 2,5-bis[4-(3,5-diphenyl-1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)

L35 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:927199 HCAPLUS
DN 141:379922
TI Preparation of pyrazole derivatives as selective phosphodiesterase 4 inhibitors
IN Hopper, Allen; Kuester, Erik; Dunn, Robert; Conticello, Richard
PA Memory Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004094411	A1	20041104	2004WO-US0011899	20040416 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004232973	A1	20041104	2004AU-000232973	20040416 <--
CA-----2522687	A1	20041104	2004CA-002522687	20040416 <--
US-20040229918	A1	20041118	2004US-000825611	20040416 <--
US-----7226930	B2	20070605		
EP-----1631568	A1	20060308	2004EP-000759965	20040416 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR--2004009888	A	20060523	2004BR-000009888	20040416 <--
CN-----1809559	A	20060726	2004CN-080017033	20040416 <--
JP--2006523719	T	20061019	2006JP-000513094	20040416 <--
MX--2005011200	A	20051214	2005MX-000011200	20051018 <--
IN---2005004777	A	20070817	2005IN-000004777	20051019 <--
US-20070203197	A1	20070830	2007US-000797151	20070501 <--
US-----7495017	B2	20090224		
PRAI 2003US-00463725P	P	20030418	<--	
2004US-000825611	A3	20040416		
2004WO-US0011899	W	20040416		

OS MARPAT 141:379922
GI



I II

AB Title (hetero)aryl pyrazole compds. I (wherein Ar = substituted Ph, pyridinyl, benzofuranyl, benzopyrazolyl, pyrazolo[4,3-b]pyridinyl; L = bond, (CH2)nCONH, (CH2)nCON(alkyl), (CH2)nNHCO, (CH2)nCONHSO2, (CH2)nSO2NH, (CH2)nSO2, (CH2)nCO2, (un)substituted alkylene optionally interrupted by O, NH, S; n = 0-3; R3 = H, (un)substituted (cyclo)alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R7, R8 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl; and pharmaceutically acceptable salts thereof] were prepared. The invention compds. exhibited improved phosphodiesterase 4 (PDE4) inhibition as compared to compds. such as rolipram and showed selectivity with regard to inhibition of other classes of PDEs. For example, 3-hydroxy-4-methoxybenzaldehyde was condensed with (S)-3-hydroxytetrahydrofuran using PPh3 and DIAD in THF to give (R)-4-methoxy-3-[(tetrahydrofuran-3-yl)oxy]benzaldehyde (66%). Reaction of the aldehyde with diethoxyphosphorylacetaldehyde tosylhydrazone in the presence of NaH in THF provided the desired pyrazole II (57%). Compds. of

L35 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
the invention blocked the human PDE4 mediated conversion of cAMP to adenosine with IC50 values ranging from 10 nM to 5000 nM. Thus, I and their pharmaceutical compns. are useful for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease (no data).

IT **784191-27-1P**, (R)-5-[4-Methoxy-3-[(tetrahydrofuran-3-yl)oxy]phenyl]-1-[4-(4-morpholinyl)phenyl]-1H-pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 innibitor; preparation of pyrazole derivs. as selective PDE4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)

IT **784191-27-1P**, (R)-5-[4-Methoxy-3-[(tetrahydrofuran-3-yl)oxy]phenyl]-1-[4-(4-morpholinyl)phenyl]-1H-pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 innibitor; preparation of pyrazole derivs. as selective PDE4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)

RN 784191-27-1 HCAPLUS

CN Morpholine, 4-[4-[5-[4-methoxy-3-[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-1H-pyrazol-1-yl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:841775 HCAPLUS

DN 141:350163

TI Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists

IN Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph

PA Merck Patent GmbH, Germany

SO Ger. Offen., 102 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE----10315572	A1	20041014	2003DE-100015572	20030405 <--
AU--2004228120	A1	20041021	2004AU-000228120	20040308 <--
CA-----2521201	A1	20041021	2004CA-002521201	20040308 <--
WO--2004089931	A1	20041021	2004WO-EP0002353	20040308 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1626967	A1	20060222	2004EP-000718277	20040308 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR--2004009164	A	20060411	2004BR-000009164	20040308 <--
CN-----1768051	A	20060503	2004CN-080008572	20040308 <--
JP--2006522035	T	20060928	2006JP-000504584	20040308 <--
US-20060264419	A1	20061123	2005US-000552065	20051005 <--
PRAI 2003DE-100015572	A	20030405 <--		
2004WO-EP0002353	W	20040308 <--		

OS MARPAT 141:350163

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I [X = CH, N; R1 = H, halo, (CH2)nHet, etc.; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, etc.; R3, R4 = H, (CH2)nCOHet, CHO, etc.; n = 0-5; Ar = (un)substituted Ph; Het = (un)substituted monoarom., bicyclic-heterocycle] and their pharmaceutically acceptable salts were prepared For example, sodium triacetoxyborohydride meditated reductive amination of 1-methyl-piperazine and aldehyde II, e.g., prepared from 2-fluoro-4,Y-dioxo-benzenebutanoic Et ester in 4-steps, afforded the dihydrochloride salt of arylpyrazole III. In 5-HT2A receptor binding assays, 167-examples of compds. I exhibited IC50 values ranging from 0.015-4.7x10-7M. Compds. I are claimed suitable as ligands of 5-HT receptors.

IT **508219-21-4 508219-26-9 508219-28-1**
508219-29-2 508219-30-5 508219-38-3
508219-39-4 508219-41-8 508219-43-0
508219-48-5 508219-51-0 508219-52-1
508219-54-3 508219-55-4 508219-56-5
508219-57-6 508219-58-7 508219-59-8
508219-60-1 508219-61-2 508219-62-3
508219-64-5 508219-65-6 508219-66-7
508219-70-3 508219-71-4 508219-72-5
508219-74-7 508219-75-8 508219-76-9
508219-77-0 508219-78-1 508219-85-0
770739-06-5 770739-09-8 770739-77-0

L35 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1053727-36-8 1053727-38-0 1053727-39-1
1053727-47-1 1053727-90-4 1053728-38-3
1053728-39-4 1053728-42-9 1053728-49-6
1053729-34-2 1053729-37-5 1053729-39-7
1053729-41-1 1053729-42-2 1053729-43-3
1053729-48-8 1053729-51-3 1053729-58-0
1053729-59-1 1053729-62-6 1053729-74-0
1053729-76-2 1053729-78-4 1053729-81-9
1053729-82-0 1053729-83-1 1053729-86-4
1053729-89-7 1053729-90-0 1053729-92-2
1053729-94-4 1053729-95-5 1053729-98-8
1053729-99-9 1053730-01-0 1053730-02-1
1053730-05-4 1053730-06-5 1053730-08-7
1053730-09-8 1053730-13-4 1053730-18-9
1053730-20-3 1053730-22-5 1053730-26-9
1053730-27-0 1053730-28-1 1053730-30-5
1053730-32-7 1053730-34-9 1053730-35-0
1053730-37-2 1053730-38-3 1053730-39-4
1053730-40-7 1053730-48-5 1053730-49-6
1053730-55-4 1053730-57-6 1053730-59-8
1053730-60-1 1053730-62-3 1053730-66-7
1053730-71-4 1053730-72-5 1053730-76-9
1053730-77-0 1053730-82-7 1053731-81-9
1053731-86-4 1053731-88-6 1053731-90-0
1053731-91-1 1053732-15-2 1053732-19-6
1053732-21-0 1053732-24-3 1053732-29-8
1053732-38-9 1053732-39-0 1053732-43-6
1053732-44-7 1053732-45-8 1053732-46-9
1053732-49-2 1053732-50-5 1053732-51-6
1053732-52-7 1053732-55-0 1053732-56-1
1053732-58-3 1053732-61-8 1053732-63-0
1053732-66-3 1053733-24-6 1053733-29-1
1053733-35-9 1053733-40-6 1053733-48-4
1053733-56-4 1053733-59-7 1053733-62-2
1053734-28-3 1053734-29-4 1053734-31-8
1053734-32-9 1053734-34-1 1053734-35-2
1053734-37-4 1053734-38-5 1053734-41-0
1053734-43-2 1053734-45-4 1053734-46-5
1053734-49-8 1053734-90-9 1053734-93-2
1053735-01-5 1053735-02-6 1053735-06-0
1053735-08-2 1053735-11-7 1053735-13-9
1053735-16-2 1053735-17-3 1053735-18-4
1053735-19-5 1053735-24-2 1053735-30-0
1053735-32-2 1053735-33-3 1053735-35-5
1053735-36-6 1053735-39-9 1053735-40-2
1053735-41-3 1053735-43-5 1053735-47-9
1053735-48-0 1053735-49-1 1053735-51-5
1053735-55-9 1053735-56-0 1053735-58-2
1053735-59-3 1053735-62-8 1053735-67-3
1053736-07-4 1053736-08-5 1063716-92-7
1063716-96-0 1063716-97-1 1063717-03-2
1063717-41-8 1063717-57-6 1063717-69-0
1063719-40-3 1073626-82-0 1073626-83-1
1073626-84-2 1073626-85-3 1073626-86-4
1073626-87-5 1073626-89-7 1073626-90-0
1073626-91-1 1073626-92-2 1073626-93-3
1073626-94-4 1073626-95-5 1073626-96-6
1073626-97-7 1073626-98-8 1073626-99-9
1073627-00-5 1073627-01-6 1073627-02-7
1073627-03-8 1073627-08-3 1073627-11-8
1073627-12-9 1073627-14-1 1073627-15-2
1073627-17-4 1073627-18-5 1073627-21-0
1073627-22-1 1073627-25-4 1073627-26-5
1073627-28-7 1073627-30-1 1073627-31-2
1073627-32-3 1073627-33-4 1073627-34-5
1073627-35-6 1073627-36-7 1073627-37-8
1073627-38-9 1073627-39-0 1073627-40-3
1073627-41-4 1073627-42-5
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

IT **1073627-43-6 1073627-44-7 1073627-45-8**
1073627-46-9 1073627-47-0 1073627-48-1
1073627-49-2 1073627-53-8 1073627-54-9

L35 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1073627-55-0 1073627-56-1 1073627-57-2
1073627-58-3 1073627-59-4 1073627-60-7
1073627-61-8 1073627-62-9 1073627-63-0
1073627-64-1 1073627-65-2 1073627-66-3
1073627-68-5 1073627-69-6 1073627-70-9
1073627-71-0 1073627-72-1 1073627-73-2
1073627-74-3 1073627-75-4 1073627-79-8
1073627-80-1 1073627-81-2 1073627-82-3
1073627-83-4 1073627-85-6 1073627-86-7
1073627-87-8 1073627-89-0 1073627-93-6
1073627-94-7 1073627-95-8 1073627-96-9
1073627-97-0 1073627-98-1 1073627-99-2
1073628-00-8 1073628-01-9 1073628-02-0
1073628-03-1 1073628-06-4 1073628-07-5
1073628-08-6 1073628-09-7 1073628-10-0
1073628-11-1 1073628-13-3 1073628-14-4
1073628-15-5 1073628-16-6 1073628-17-7
1073628-18-8 1073628-19-9 1073628-20-2
1073628-21-3 1073628-22-4 1073628-23-5
1073628-24-6 1073628-25-7 1073628-27-9
1073628-28-0 1073628-29-1 1073628-30-4
1073628-31-5 1073628-32-6 1073628-33-7
1073628-34-8 1073628-36-0 1073628-39-3
1073628-40-6 1073628-42-8 1073628-43-9
1073628-44-0 1073628-45-1 1073628-46-2
1073628-48-4 1073628-50-8 1073628-51-9
1073628-52-0 1073628-53-1 1073628-54-2
1073628-55-3 1073628-56-4 1073628-57-5
1073628-59-7 1073628-60-0 1073628-61-1
1073628-62-2 1073628-63-3 1073628-64-4
1073628-68-8 1073628-69-9 1073628-70-2
1073628-71-3 1073628-73-5 1073628-74-6
1073628-75-7 1073628-76-8 1073628-80-4
1073628-81-5 1073628-83-7 1073628-85-9
1073628-88-2 1073628-90-6 1073628-92-8
1073628-93-9 1073628-97-3 1073628-99-5
1073629-00-1 1073629-02-3 1073629-14-7
1073629-15-8 1073638-49-9 1073638-50-2
1073638-51-3 1073638-52-4 1073638-57-9
1073638-58-0 1073638-60-4 1073638-61-5
1073638-66-0 1073638-67-1 1073638-69-3
1073638-70-6 1073638-72-8 1073638-73-9
1073638-75-1 1073638-76-2 1073638-77-3
1073638-78-4 1073638-79-5 1073638-81-9
1073638-82-0 1073638-86-4 1073638-87-5
1073638-88-6 1073638-89-7 1073638-91-1
1073638-92-2 1073638-93-3 1073638-94-4
1073638-95-5 1073638-96-6 1073638-97-7
1073638-98-8 1073638-99-9 1073639-00-5
1073639-01-6 1073639-03-8 1073639-04-9
1073639-06-1 1073639-07-2 1073639-08-3
1073639-09-4 1073639-13-0 1073639-14-1
1073639-16-3 1073639-17-4 1073639-18-5
1073639-19-6 1073639-21-0 1073639-22-1
1073639-23-2 1073639-24-3 1073639-25-4
1073639-27-6 1073639-28-7 1073639-29-8
1073639-30-1 1073639-31-2 1073639-32-3
1073639-34-5 1073639-35-6 1073639-36-7
1073639-37-8 1073639-38-9 1073639-43-6
1073639-44-7 1073639-45-8 1073639-47-0
1073639-48-1 1073639-49-2 1073639-50-5
1073639-51-6 1073639-52-7 1073639-53-8
1073639-54-9 1073639-56-1 1073639-57-2
1073639-58-3 1073639-59-4 1073639-60-7
1073639-61-8 1073639-62-9 1073639-63-0
1073639-64-1 1073639-65-2 1073639-66-3
1073639-72-1 1073639-73-2 1073639-74-3
1073639-75-4 1073639-76-5 1073639-77-6
1073639-78-7 1073639-79-8 1073639-80-1
1073639-81-2 1073639-82-3 1073639-83-4
1073639-84-5 1073639-85-6 1073639-86-7
1073639-87-8 1073639-89-0 1073639-90-3
1073639-91-4 1073639-92-5 1073639-93-6
1073639-97-0 1073639-98-1 1073639-99-2

L35 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1073640-00-2 1073640-02-4 1073640-03-5
1073640-05-7 1073640-06-8 1073640-07-9
1073640-08-0 1073640-09-1
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

IT 1073640-10-4 1073640-11-5 1073640-12-6
1073640-13-7 1073640-14-8 1073640-15-9
1073640-18-2 1073640-19-3 1073640-20-6
1073640-21-7 1073640-22-8 1073640-26-2
1073640-27-3 1073640-28-4 1073640-29-5
1073640-31-9 1073640-32-0 1073640-33-1
1073640-34-2 1073640-35-3 1073640-36-4
1073640-37-5 1073640-38-6 1073640-39-7
1073640-40-0 1073640-41-1 1073640-42-2
1073640-43-3 1073640-44-4 1073640-46-6
1073640-47-7 1073640-48-8 1073640-49-9
1073640-52-4 1073640-55-7 1073640-57-9
1073640-58-0 1073640-59-1 1073640-60-4
1073640-61-5 1073640-62-6 1073640-63-7
1073640-64-8 1073640-65-9 1073640-66-0
1073640-67-1 1073640-69-3 1073640-70-6
1073640-71-7 1073640-72-8 1073640-73-9
1073640-74-0 1073640-75-1 1073640-76-2
1073640-77-3 1073640-82-0 1073640-83-1
1073640-84-2 1073640-85-3 1073640-86-4
1073640-87-5 1073640-88-6 1073640-89-7
1073640-91-1 1073640-92-2 1073640-93-3
1073640-94-4 1073640-96-6 1073640-97-7
1073640-98-8 1073640-99-9 1073641-00-5
1073641-01-6 1073641-02-7 1073641-03-8
1073641-04-9 1073641-05-0 1073641-08-3
1073641-11-8 1073641-12-9 1073641-13-0
1073641-14-1 1073641-15-2 1073641-16-3
1073641-17-4 1073641-18-5 1073641-19-6
1073641-20-9 1073641-21-0 1073641-22-1
1073641-23-2 1073641-24-3 1073641-25-4
1073641-26-5 1073641-27-6 1073641-28-7
1073641-29-8 1073641-30-1 1073641-31-2
1073641-35-6
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

IT 508219-08-7P 508219-09-8P 508219-10-1P
508219-13-4P 508219-14-5P 508219-15-6P
508219-16-7P 508219-17-8P 508219-18-9P
508219-19-0P 508219-20-3P 508219-22-5P
508219-23-6P 508219-24-7P 508219-27-0P
508219-31-6P 508219-32-7P 508219-33-8P
508219-34-9P 508219-35-0P 508219-36-1P
508219-40-7P 508219-42-9P 508219-44-1P
508219-46-3P 508219-47-4P 508219-49-6P
508219-73-6P 508219-79-2P 508219-86-1P
770739-50-9P 770739-73-6P 770739-84-9P
770739-98-5P 770740-20-0P 770740-35-7P
770740-36-8P 774583-04-9P 774583-05-0P
774583-06-1P 774583-08-3P 774583-16-3P
774583-47-0P 774583-60-7P 774583-61-8P
774583-62-9P 774583-65-2P 774583-70-9P
774583-73-2P 774583-75-4P 774583-77-6P
774583-80-1P 774583-81-2P 774583-82-3P
774583-84-5P 774583-85-6P 774583-86-7P
774583-87-8P 774583-88-9P 774583-89-0P
774583-90-3P 774583-91-4P 774583-92-5P
774583-93-6P 774583-94-7P 774583-95-8P
774583-96-9P 774584-02-0P 774584-04-2P
774584-06-4P 774584-08-6P 774584-10-0P
774584-12-2P 774584-14-4P 774584-16-6P
774584-17-7P 774584-18-8P 774584-19-9P
774584-20-2P 774584-21-3P 774584-22-4P

L35 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L35 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

774584-23-5P 774584-24-6P 774584-25-7P
774584-26-8P 774584-27-9P 774584-30-4P
774584-31-5P 774584-32-6P 774584-33-7P
774584-34-8P 774584-35-9P 774584-36-0P
774584-37-1P 774584-38-2P 774584-39-3P
774584-40-6P 774584-41-7P 774584-42-8P
774584-43-9P 774584-44-0P 774584-45-1P
774584-46-2P 774584-47-3P 774584-48-4P
774584-49-5P 774584-50-8P 774584-51-9P
774584-52-0P 774584-53-1P 774584-54-2P
774584-55-3P 774584-56-4P 774584-57-5P
774584-58-6P 774584-59-7P 774584-60-0P
774584-61-1P 774584-62-2P 774584-63-3P
774584-64-4P 774584-65-5P 774584-66-6P
774584-67-7P 774584-68-8P 774584-69-9P
774584-70-2P 774584-71-3P 774584-72-4P
774584-73-5P 774584-74-6P 774584-75-7P
774584-76-8P 774584-77-9P 774584-78-0P
774584-79-1P 774584-80-4P 774584-81-5P
774584-82-6P 774584-83-7P 774584-84-8P
774584-88-9P 774584-86-0P 774584-88-2P
774584-89-3P 774584-90-6P 774584-91-7P
774584-92-8P 774584-93-9P 774584-94-0P
774584-95-1P 774584-96-2P 774584-97-3P
774584-98-4P 774584-99-5P 774585-00-1P
774585-01-2P 774585-02-3P 774585-03-4P
774585-04-5P 774585-05-6P 774585-06-7P
774585-07-8P 774585-08-9P 774585-09-0P
774585-10-3P 774585-11-4P 774585-12-5P
774585-13-6P 774585-14-7P 774585-15-8P
774585-16-9P 774585-17-0P 774585-18-1P
774585-20-5P 774585-21-6P 774585-22-7P
774585-24-9P 774585-25-0P 774585-27-2P
774585-28-3P 774585-30-7P 774585-31-8P
774585-33-0P 774585-34-1P 774585-35-2P
774585-36-3P 774585-37-4P 774585-38-5P
774585-39-6P 774585-40-9P 774585-41-0P
774585-42-1P 774585-43-2P 774585-44-3P
774585-45-4P 774585-46-5P 774585-47-6P
774585-48-7P 774585-49-8P 774585-51-2P
774585-52-3P 774585-53-4P 774585-55-6P
774585-56-7P 774585-57-8P 774585-58-9P
774585-59-0P 774585-60-3P 774585-61-4P
774585-62-5P 774585-63-6P 774585-64-7P
774585-66-9P 774585-67-0P 774585-68-1P
774585-69-2P 774585-70-5P 774585-71-6P
774585-73-8P 774585-74-9P 774585-75-0P
774585-76-1P 774585-77-2P 774585-78-3P
774585-80-7P 774585-81-8P 774585-82-9P
774593-64-5P 774593-66-7P 774593-70-3P
775318-34-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

IT 508219-21-4
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

RN 508219-21-4 HCAPLUS
CN Thiazolidine, 3-[[1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L35 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:841772 HCAPLUS
DN 141:332186
TI Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.
IN Schadt, Oliver; Arlt, Michael; Finsinger, Dirk; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 78 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE----10315569	A1	20041014	2003DE-100015569	20030405 <--
AU--2004228124	A1	20041021	2004AU-000228124	20040310 <--
CA-----2521227	A1	20041021	2004CA-002521227	20040310 <--
WO--2004089932	A1	20041021	2004WO-EP0002453	20040310 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1611122	A1	20060104	2004EP-000718926	20040310 <--
EP-----1611122	B1	20070613		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR--2004008986	A	20060328	2004BR-000008986	20040310 <--
CN-----1768052	A	20060503	2004CN-080008603	20040310 <--
JP--2006522039	T	20060928	2006JP-000504620	20040310 <--
AT------364601	T	20070715	2004AT-000718926	20040310 <--
ES-----2287710	T3	20071216	2004ES-000718926	20040310 <--
US-20070010531	A1	20070111	2005US-000552064	20051005 <--
PRAI 2003DE-100015569	A	20030405 <--		
2004WO-EP0002453	W	20040310		

OS MARPAT 141:332186
GI



I

AB Title compds. [I; R1 = H, A, halo, (CH2)nAr, cycloalkyl, CF3, NO2, cyano, C(NH)NOH, OCF3; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, CF3; R3, R4 = H, (CH2)nCO2R5, (CH2)nCOHet, CHO, (CH2)nOR5, (CH2)nHet, CH:NOA, etc.; R5 = H, A; A = alkyl, alkoxy, alkenyl, alkoxyalkyl; Ar = (substituted) Ph; Het = (aromatic) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; X = N, CH; with provisos], were prepared Thus, [1-(4'-fluorobiphen-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]methyl(1-methylpyrrolidin-3-yl)amine showed 5-HT2A activity with IC50 = 5.14E-10.

IT 1054281-99-0 1054282-00-6 1054282-01-7
1054282-02-8 1054282-03-9 1054282-04-0
1054282-05-1 1054282-06-2 1054282-07-3
1054282-08-4 1054282-09-5 1054282-10-8
1054282-11-9 1054282-12-0 1054282-13-1
1054282-14-2 1054282-15-3 1054282-16-4
1054282-17-5 1054282-18-6 1054282-19-7
1054282-20-0 1054282-21-1 1054282-22-2
1054282-23-3 1054282-24-4 1054282-25-5
1054282-26-6 1054282-27-7 1054282-28-8
1054282-29-9 1054282-30-2 1054282-31-3
1054282-32-4 1054282-33-5 1054282-34-6

L35 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1054282-35-7 1054282-36-8 1054282-37-9
1054282-38-0 1054282-39-1 1054282-40-4
1054282-41-5 1054282-42-6 1054282-43-7
1054282-44-8 1054282-45-9 1054282-46-0
1054282-47-1 1054282-48-2 1054282-49-3
1054282-50-6 1054282-51-7 1054282-52-8
1054282-53-9 1054282-54-0 1054282-55-1
1054282-56-2 1054282-57-3 1054282-58-4
1054282-59-5 1054282-60-8 1054282-61-9
1054282-62-0 1054282-63-1 1054282-64-2
1054282-65-3 1054282-66-4 1054282-67-5
1054282-68-6 1054282-69-7 1054282-70-0
1054282-71-1 1054282-72-2 1054282-73-3
1054282-74-4 1054282-75-5 1054282-76-6
1054282-77-7 1054282-78-8 1054282-79-9
1054282-80-2 1054282-81-3 1054282-82-4
1054282-83-5 1054282-84-6 1054282-85-7
1054282-86-8 1054282-87-9 1054282-88-0
1054282-89-1 1054282-90-4 1054282-91-5
1054282-92-6 1054282-93-7 1054282-94-8
1054282-95-9 1054282-96-0 1054282-97-1
1054282-98-2 1054282-99-3 1054283-00-9
1054283-01-0 1054283-02-1 1054283-03-2
1054283-04-3 1054283-05-4 1054283-06-5
1054283-07-6 1054283-08-7 1054283-09-8
1054283-10-1 1054283-11-2 1054283-12-3
1054283-13-4 1054283-14-5 1054283-15-6
1054283-16-7 1054283-17-8 1054283-18-9
1054283-19-0 1054283-20-3 1054283-21-4
1054283-22-5 1054283-23-6 1054283-24-7
1054283-25-8 1054283-26-9 1054283-27-0
1054283-28-1 1054283-29-2 1054283-30-5
1054283-31-6 1054283-32-7 1054283-33-8
1054283-34-9 1054283-35-0 1054283-36-1
1054283-37-2 1054283-38-3 1054283-39-4
1054283-40-7 1054283-41-8 1054283-42-9
1054283-43-0 1054283-44-1 1054283-45-2
1054283-46-3 1054283-47-4 1054283-48-5
1054283-49-6 1054283-50-9 1054283-51-0
1054283-52-1 1054283-53-2 1054283-54-3
1054283-55-4 1054283-56-5 1054283-57-6
1054283-58-7 1054283-59-8 1054283-60-1
1054283-61-2 1054283-62-3 1054283-63-4
1054283-64-5 1054283-65-6 1054283-66-7
1054283-67-8 1054283-68-9 1054283-69-0
1054283-70-3 1054283-71-4 1054283-72-5
1054283-73-6 1054283-74-7 1054283-75-8
1054283-76-9 1054283-77-0 1054283-78-1
1054283-79-2 1054283-80-5 1054283-81-6
1054283-82-7 1054283-83-8 1054283-84-9
1054283-85-0 1054283-86-1 1054283-87-2
1054283-88-3 1054283-89-4 1054283-90-7
1054283-91-8 1054283-92-9 1054283-93-0
1054283-94-1 1054283-95-2 1054283-96-3
1054283-97-4 1054283-98-5 1054283-99-6
1054284-00-2 1054284-01-3 1054284-02-4
1054284-03-5 1054284-04-6 1054284-05-7
1054284-06-8 1054284-07-9 1054284-08-0
1054284-09-1 1054284-10-4 1054284-11-5
1054284-12-6 1054284-13-7 1054284-14-8
1054284-15-9 1054284-16-0 1054284-17-1
1054284-18-2 1054284-19-3 1054284-20-6
1054284-21-7 1054284-22-8 1054284-23-9
1054284-24-0 1054284-25-1 1054284-26-2
1054284-27-3 1054284-28-4 1054284-29-5
1054284-30-8 1054284-31-9 1054284-32-0
1054284-33-1 1054284-34-2 1054284-35-3
1054284-36-4 1054284-37-5

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C

L35 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

receptor antagonists.)

IT 1054284-38-6 1054284-39-7 1054284-40-0
1054284-41-1 1054284-42-2 1054284-43-3
1054284-44-4 1054284-45-5 1054284-46-6
1054284-47-7 1054284-48-8 1054284-49-9
1054284-50-2 1054284-51-3 1054284-52-4
1054284-53-5 1054284-54-6 1054284-55-7
1054284-56-8 1054284-57-9 1054284-58-0
1054284-59-1 1054284-60-4 1054284-61-5
1054284-62-6 1054284-63-7 1054284-64-8
1054284-65-9 1054284-66-0 1054284-67-1
1054284-68-2 1054284-69-3 1054284-70-6
1054284-71-7 1054284-72-8 1054284-73-9
1054284-74-0 1054284-75-1 1054284-76-2
1054284-77-3 1054284-78-4 1054284-79-5
1054284-80-8 1054284-81-9 1054284-82-0
1054284-83-1 1054284-84-2 1054284-85-3
1054284-86-4 1054284-87-5 1054284-88-6
1054284-89-7 1054284-90-0 1054284-91-1
1054284-92-2 1054284-93-3 1054284-94-4
1054284-95-5 1054284-96-6 1054284-97-7
1054284-98-8 1054284-99-9 1054285-00-5
1054285-01-6 1054285-02-7 1054285-03-8
1054285-04-9 1054285-05-0 1054285-06-1
1054285-07-2 1054285-08-3 1054285-09-4
1054285-10-7 1054285-11-8 1054285-12-9
1054285-13-0 1054285-14-1 1054285-15-2
1054285-16-3 1054285-17-4 1054285-18-5
1054285-19-6 1054285-20-9 1054285-21-0
1054285-22-1 1054285-23-2 1054285-24-3
1054285-25-4 1054285-26-5 1054285-27-6
1054285-28-7 1054285-29-8 1054285-30-1
1054285-31-2 1054285-32-3 1054285-33-4
1054285-34-5 1054285-35-6 1054285-36-7
1054285-37-8 1054285-38-9 1054285-39-0
1054285-40-3 1054285-41-4 1054285-42-5
1054285-43-6 1054285-44-7 1054285-45-8
1054285-46-9 1054285-47-0 1054285-48-1
1054285-49-2 1054285-50-5 1054285-51-6
1054285-52-7 1054285-53-8 1054285-54-9
1054285-55-0 1054285-56-1 1054285-57-2
1054285-58-3 1054285-59-4 1054285-60-7
1054285-61-8 1054285-62-9 1054285-63-0
1054285-64-1 1054285-65-2 1054285-66-3
1054285-67-4 1054285-68-5 1054285-69-6
1054285-70-9 1054285-71-0 1054285-72-1
1054285-73-2 1054285-74-3 1054285-75-4
1054285-76-5 1054285-77-6 1054285-78-7
1054285-79-8 1054285-80-1 1054285-81-2
1054285-82-3 1054285-83-4 1054285-84-5
1054285-85-6 1054285-86-7 1054285-87-8
1054285-88-9 1054285-89-0 1054285-90-3
1054285-91-4 1054285-92-5 1054285-93-6
1054285-94-7 1054285-95-8 1054285-96-9
1054285-97-0 1054285-98-1 1054285-99-2
1054286-00-8 1054286-01-9 1054286-02-0
1054286-03-1 1054286-04-2 1054286-05-3
1054286-06-4 1054286-07-5 1054286-08-6
1054286-09-7 1054286-10-0 1054286-11-1
1054286-12-2 1054286-13-3 1054286-14-4
1054286-15-5 1054286-16-6 1054286-17-7
1054286-18-8 1054286-19-9 1054286-20-2
1054286-21-3 1054286-22-4 1054286-23-5
1054286-24-6 1054286-25-7 1054286-26-8
1054286-27-9 1054286-28-0 1054286-29-1
1054286-30-4 1054286-31-5 1054286-32-6
1054286-33-7 1054286-34-8 1054286-35-9
1054286-36-0 1054286-37-1 1054286-38-2
1054286-39-3 1054286-40-6 1054286-41-7
1054286-42-8 1054286-43-9 1054286-44-0

L35 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1054286-45-1 1054286-46-2 1054286-47-3
1054286-48-4 1054286-49-5 1054286-50-8
1054286-51-9 1054286-52-0 1054286-53-1
1054286-54-2 1054286-55-3 1054286-56-4
1054286-57-5 1054286-58-6 1054286-59-7
1054286-60-0 1054286-61-1 1054286-62-2
1054286-63-3 1054286-64-4 1054286-65-5
1054286-66-6 1054286-67-7 1054286-68-8
1054286-69-9 1054286-70-2 1054286-71-3
1054286-72-4 1054286-73-5 1054286-74-6
1054286-75-7 1054286-76-8

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)

IT 1054286-77-9 1054286-78-0 1054286-79-1
1054286-80-4 1054286-81-5 1054286-82-6
1054286-83-7 1054286-84-8 1054286-85-9
1054286-86-0 1054286-87-1 1054286-88-2
1054286-89-3 1054286-90-6 1054286-91-7
1054286-92-8 1054286-93-9 1054286-94-0
1054286-95-1 1054286-96-2 1054286-97-3

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)

IT 508219-09-8 508219-31-6 770739-06-5
770739-07-6 770739-08-7 770739-09-8
770739-10-1 770739-11-2 770739-12-3
770739-13-4 770739-14-5 770739-15-6
770739-16-7 770739-17-8 770739-18-9
770739-19-0 770739-20-3 770739-21-4
770739-22-5 770739-23-6 770739-24-7
770739-25-8 770739-26-9 770739-27-0
770739-28-1 770739-29-2 770739-30-5
770739-31-6 770739-32-7 770739-33-8
770739-34-9 770739-35-0 770739-36-1
770739-37-2 770739-38-3 770739-39-4
770739-40-7 770739-41-8 770739-42-9
770739-43-0 770739-44-1 770739-45-2
770739-46-3 770739-47-4 770739-48-5
770739-49-6 770739-50-9 770739-51-0
770739-52-1 770739-53-2 770739-54-3
770739-55-4 770739-56-5 770739-57-6
770739-58-7 770739-59-8 770739-60-1
770739-61-2 770739-63-4 770739-64-5
770739-65-6 770739-66-7 770739-67-8
770739-68-9 770739-69-0 770739-70-3
770739-71-4 770739-72-5 770739-73-6
770739-74-7 770739-75-8 770739-76-9
770739-77-0 770739-78-1 770739-79-2
770739-80-5 770739-81-6 770739-82-7
770739-83-8 770739-84-9 770739-85-0
770739-86-1 770739-87-2 770739-88-3
770739-89-4 770739-90-7 770739-91-8
770739-92-9 770739-93-0 770739-94-1
770739-95-2 770739-96-3 770739-97-4
770739-98-5 770739-99-6 770740-00-6
770740-01-7 770740-02-8 770740-03-9
770740-04-0 770740-05-1 770740-06-2
770740-07-3 770740-08-4 770740-09-5
770740-10-8 770740-11-9 770740-12-0
770740-14-2 770740-15-3 770740-16-4
770740-17-5 770740-18-6 770740-19-7
770740-20-0 770740-21-1 770740-22-2
770740-23-3 770740-24-4 770740-25-5
770740-26-6 770740-27-7 770740-28-8
770740-29-9 770740-30-2 770740-33-5
770740-34-6 770740-35-7 770740-36-8
770740-37-9 770740-38-0 770740-39-1
770740-40-4 770740-41-5 770740-42-6
770740-43-7 770740-44-8 770740-45-9
770740-46-0 770740-47-1 770740-48-2
770740-49-3 770740-50-6 770740-52-8
770740-53-9 770740-54-0 770740-55-1
770740-56-2 770740-57-3 770740-59-5

L35 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

770740-60-8 770740-61-9 770740-62-0
770740-63-1 770740-64-2 770740-65-3
770740-66-4 770740-67-5 770740-68-6
770740-69-7 770740-70-0 770740-71-1
770740-72-2 770740-73-3 771525-15-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists)

IT 1054281-99-0

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)

RN 1054281-99-0 HCAPLUS

CN 1H-Pyrazole-4-ethanol, 1-(3'-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl)-5-(2-furanyl)- (CA INDEX NAME)



L35 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:780554 HCAPLUS
DN 141:301422
TI Preparation of heterocyclic ligands for acid-stabilized insulin analogs
IN Ostergaard, Soren; Olsen, Helle Birk; Kaarsholm, Niels C.; Madsen, Peter; Jakobsen, Palle; Ludvigsen, Svend; Schluckebier, Gerd; Steensgaard, Dorte Bjerre; Petersen, Anders Klarskov
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 473 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004080480	A1	20040923	2004WO-DK000158	20040311 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004218808	A1	20040923	2004AU-000218808	20040311 <--
CA-----2522818	A1	20040923	2004CA-002522818	20040311 <--
EP-----1610812	A1	20060104	2004EP-000719368	20040311 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR--2004008229	A	20060221	2004BR-000008229	20040311 <--
CN-----1787833	A	20060614	2004CN-080012690	20040311 <--
JP--2007523842	T	20070823	2006JP-000504320	20040311 <--
US-20060069013	A1	20060330	2005US-000227760	20050912 <--
NO--2005004555	A	20051117	2005NO-000004555	20051004 <--
PRAI 2003DK-000000365	A	20030311	<--	
2003US-00455400P	P	20030317	<--	
2004WO-DK000158	A	20040311		

OS MARPAT 141:301422
AB Novel ligands for the His-B10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin prepns. are disclosed. A mixture of 4-aminobenzonitrile, sodium azide and ammonium chloride in DMF was heated at 125° for 16 h. The cooled mixture was filtered and the filtrate was concentrated to give 5-(4-aminophenyl)-2H-tetrazole. This was used as the ligand for His-B10 Zn2+ sites of the R-state insulin hexamer.
IT **1055980-10-3**
RL: PRPH (Prophetic)
(Preparation of heterocyclic ligands for acid-stabilized insulin analogs)
IT **1055980-10-3**
RL: PRPH (Prophetic)
(Preparation of heterocyclic ligands for acid-stabilized insulin analogs)
RN 1055980-10-3 HCAPLUS
CN 4-Thiazolidinone, 5-[[4-(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)phenyl]methylene]-2-thioxo-, (5E)- (CA INDEX NAME)

Double bond geometry as shown.

L35 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:515606 HCAPLUS
DN 141:79119
TI Organic electroluminescent device material and organic electroluminescent device using same
IN Iwakuma, Toshiniro; Tomita, Seiji; Arakane, Takashi
PA Idemitsu Kosan Co., Ltd., Japan
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004053019	A1	20040624	2003WO-JP0015874	20031211 <--
W: CN, IN, JP, KR, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
EP-----1571193	A1	20050907	2003EP-000778817	20031211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
CN-----1723258	A	20060118	2003CN-080105706	20031211 <--
CN---100338172	C	20070919		
US-20060251918	A1	20061109	2005US-000538023	20050607 <--
IN---200501208	A	20070622	2005IN-000001208	20050610 <--
PRAI 2002JP-000360134	A	20021212	<--	
2003WO-JP0015874	W	20031211	<--	

OS MARPAT 141:79119
GI



I

AB An organic electroluminescent (EL) device material composed of a compound having a specific N-containing condensed ring structure is disclosed. The organic electroluminescent device material is represented by I [X1-8 = C and N, at least one of X1-8 is nitrogen; R1-8 connected to carbon is substitution groups that may be linked to form a ring when the substitution groups are located next to each other, R1-8 connected to nitrogen represents lone pair electrons; R9 = substitution group]. An organic EL device wherein ≥1 organic thin-film layers are interposed between a cathode and an anode and at least 1 of the organic thin-film layers contains the organic EL device material is also disclosed. The organic EL device material enables to form a long-life organic EL device which uses phosphorescent emission and has a high luminous efficiency. The organic EL device is fabricated using this organic EL device material.
IT **710948-10-0P**
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(phosphorescent organic electroluminescent device material)
IT **710948-10-0P**
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(phosphorescent organic electroluminescent device material)
RN 710948-10-0 HCAPLUS
CN 5H-Pyrido[4,3-b]indole, 5-[4-(3,5-diphenyl-1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)

L35 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L35 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:493684 HCAPLUS
DN 141:54327
TI Preparation of pyrazole derivatives useful as COX-1 inhibitors
IN Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko; Okumura, Kazuo; Nakamura, Katsuya
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 436 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004050632	A1	20040617	2003WO-JP0014489	20031114 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2505945	A1	20040617	2003CA-002505945	20031114 <--
AU--2003302635	A1	20040623	2003AU-0003026635	20031114 <--
EP-----1567503	A1	20050831	2003EP-000812289	20031114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR--2003016332	A	20050927	2003BR-000016332	20031114 <--
CN-----1717393	A	20060104	2003CN-080104548	20031114 <--
JP--2006514095	T	20060427	2004JP-000570721	20031114 <--
NZ------540515	A	20080131	2003NZ-000540515	20031114 <--
MX---2005005742	A	20050816	2005MX-000005742	20050530 <--
IN---200501453	A	20070622	2005IN-000001453	20050629 <--
NO---2005003215	A	20050901	2005NO-000003215	20050630 <--
PRAI 2002AU-000953019	A	20021202	<--	
2002AU-000953602	A	20021230	<--	
2003AU-000902015	A	20030429	<--	
2003WO-JP0014489	W	20031114	<--	

OS MARPAT 141:54327
GI



I

AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc. ; R4 = H, CN, OH, etc.; X = O, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.
IT **705938-81-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)

L35 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT **705938-82-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
IT **705938-81-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705938-81-4 HCAPLUS
CN Benzeneethanol, 4-[1-[4-(1H-pyrrol-1-yl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, 1-acetate (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:493568 HCAPLUS
DN 141:54325
TI Preparation of pyrazole derivatives useful as COX-1 inhibitors
IN Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko; Okumura, Kazuo; Nakamura, Katsuya
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 142 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20040116475	A1	20040617	2003US-000706999	20031114 <--
US-----7183306	B2	20070227		
CN-----1717393	A	20060104	2003CN-080104548	20031114 <--
US-20070112037	A1	20070517	2006US-000610230	20061213 <--
PRAI 2002AU-000953019	A	20021202	<--	
2002AU-000953602	A	20021230	<--	
2003AU-000902015	A	20030429	<--	
2003US-000706999	A3	20031114	<--	

OS MARPAT 141:54325
GI



I

AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc. ; R4 = H, CN, OH, etc.; X = O, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.
IT **705938-81-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
IT **705938-82-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
IT **705938-81-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705938-81-4 HCAPLUS
CN Benzeneethanol, 4-[1-[4-(1H-pyrrol-1-yl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, 1-acetate (CA INDEX NAME)

L35 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:355031 HCAPLUS
DN 140:365418
TI Material for organic electroluminescence element, and organic electroluminescence element using the same
IN Tomita, Seiji; Iwakuma, Toshihiro; Arakane, Takashi; Yasuda, Hiroya; Hosokawa, Chishio
PA Idemitsu Kosan Co., Ltd., Japan
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004035709	A1	20040429	2003WO-JP0013186	20031015 <--
W: CN, IN, JP, KR, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
EP-----1555305	A1	20050720	2003EP-000754133	20031015 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
CN-----1705731	A	20051207	2003CN-080101772	20031015 <--
IN---200500654	A	20070622	2005IN-000000654	20050418 <--
US-20060141284	A1	20060629	2005US-000532001	20050810 <--
PRAI 2002JP-000305375	A	20021021	<--	
2003WO-JP0013186	W	20031015	<--	

OS MARPAT 140:365418
AB A material for an organic electroluminescence (EL) element comprising a compound having a specific N-containing condensed ring structure; and an organic EL element which comprises a cathode, an anode and, sandwiched between them, ≥1 of organic thin film layers, wherein at least 1 organic thin layer is an organic EL layer containing the above material for an organic EL element. The material for an organic EL element can provide an organic EL element being capable of achieving high luminous efficiency with a low elec. voltage.
IT **682801-12-3P**
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(host material for phosphorescent guest in; phosphorescent organic electroluminescent device)
IT **682801-12-3P**
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(host material for phosphorescent guest in; phosphorescent organic electroluminescent device)
RN 682801-12-3 HCAPLUS
CN 5H-Cyclooct[b]indole, 5-[4-(3,5-diphenyl-1H-pyrazol-1-yl)phenyl]-6,7,8,9,10,11-hexahydro- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Preparation); USES (Uses)
(red org. light-emitting compd. and org. light-emitting device comprising the same)
IT **606127-16-6P**
RL: DEV (Device component use); PNU (Preparation, unclassified); PREP (Preparation); USES (Uses)
(red organic light-emitting compound and organic light-emitting device comprising the same)
RN 606127-16-6 HCAPLUS
CN Propanedinitrile, 2-[2-[2-[4-(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)phenyl]ethenyl]-6-phenyl-4H-pyran-4-ylidene]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:757790 HCAPLUS
DN 139:283126
TI Red organic light-emitting compound and organic light-emitting device comprising the same
IN Kim, Ki-seok; Hwang, Ha-geun
PA Neoview Co., Ltd., S. Korea
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2003078542	A1	20030925	2003WO-KR0000536	20030319 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR--2003075497	A	20030926	2002KR-000014757	20020319 <--
KR--2004069436	A	20040806	2003KR-000005827	20030129 <--
AU--2003215943	A1	20030929	2003AU-000215943	20030319 <--
US-20060022584	A1	20060202	2004US-000507905	20040916 <--
US-----7211335	B2	20070501		
PRAI 2002KR-000014757	A	20020319	<--	
2003KR-000005827	A	20030129	<--	
2003WO-KR0000536	W	20030319	<--	

OS MARPAT 139:283126
GI



I

AB A red organic light-emitting compound with the formula I which has a superior heat-resistance and is capable of adjusting the color of the emitted light, and an organic light-emitting device including the compound are disclosed. The organic light-emitting compound has the structure of the following chemical formula, and the organic light-emitting device includes the 1st electrode having a high work function; the 2nd electrode having a low work function; and at least one organic layer formed between the 1st electrode and the 2nd electrode, which includes the red organic light-emitting compound, wherein, X is C, O, S, SO2 or N; Y is S or -CR11 = CR12-; R1, R2, R3, R11 and R12 can be the same or different, and are H, alkyl group of 1 to 20 C atoms, alkoxy group of 1 to 5 C atoms, aryl or heteroaryl group of 4 to 24 C atoms, heterocyclic group of 4 to 6 C atoms, or fused ring group of 4 to 24 C atoms; R4 and R5 can be the same or different, and are the functional group defined for R1 or O; when R4 and R5 are O, R4 and R5 can be connected to form a heterocyclic ring; is the functional group defined for R1 or amine group; and n is 1, 2 or 3.
IT **606127-16-6P 606127-17-7P 606127-19-9P**
606127-21-3P 606127-23-5P 606127-25-7P
RL: DEV (Device component use); PNU (Preparation, unclassified); PREP

L35 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:279804 HCAPLUS
DN 138:294714
TI Organic electroluminescent device using pyrazole or pyrazoline
IN Suzuki, Koichi; Ueno, Kazunori; Senoo, Akihiro
PA Canon Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP--2003109765	A	20030411	2001JP-000300548	20010928 <--
PRAI 2001JP-000300548		20010928	<--	

OS MARPAT 138:294714
GI



I

AB The invention refers to an organic electroluminescent device comprising pyrazole or pyrazoline I [R1 = H, alkyl, (un)substituted aralkyl, aryl, heterocyclic, condensed polycyclic aromatic or heterocyclic; Ar1-3 = (un)substituted aryl, heterocyclic, condensed polycyclic aromatic or heterocyclic; at least two of R1, Ar1-3 are (un)substituted condensed polycyclic aromatic or heterocyclic groups].
IT **504414-90-8 504415-11-6**
RL: DEV (Device component use); USES (Uses)
(organic electroluminescent device using pyrazole or pyrazoline)
IT **504414-90-8**
RL: DEV (Device component use); USES (Uses)
(organic electroluminescent device using pyrazole or pyrazoline)
RN 504414-90-8 HCAPLUS
CN 1H-Pyrazole-4-carbonitrile, 1-[4-(9-anthracenyl)phenyl]-3,5-di-1,10-phenanthrolin-5-yl- (CA INDEX NAME)



L35 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:279562 HCAPLUS

DN 138:304276

TI Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases

PA Merck Patent G.m.b.H., Germany; Yamanouchi Pharmaceutical Co.

SO Ger. Offen., 62 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE----10149370	A1	20030410	2001DE-100049370	20011006 <--
WO--2003031435	A1	20030417	2002WO-EP0010172	20020911 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2002342675	A1	20030422	2002AU-000342675	20020911 <--
PRAI 2001DE-100049370	A	20011006	<--	
2002WO-EP0010172	W	20020911	<--	

OS MARPAT 138:304276

GI



I

II



III



IV

AB Title compds. I [X = CH, N; R1 = H, A, halo, etc.; R2 = Ph, p-chlorophenyl; R3, R4 = H, (CH2)nCO2R5, CHO, etc.; R5 = H, A; A = alkyl, alkenyl, alkoxyalkyl, etc.; n = 0-5] and their pharmaceutically acceptable salts were prepared For example, condensation of enamine II e.g., prepared from 1,1-dimethoxy-N,N-dimethylmethanamine and 2-fluoro-β-oxo-benzenepropanoic acid Et ester, and aryl hydrazine III, e.g., prepared from 2-chloro-5-nitropyridine in 3-steps, provided pyrazole IV (no yield provided). In glycine transporter protein inhibition studies, approx. 71-examples of compds. I exhibited IC50 values ranging from 0.15 - 8.7 μM, e.g., the IC50 value of pyrazole IV = 2.5 μM. Compds. I are claimed useful for the treatment of schizophrenia, depression, dementia, etc.

IT **774583-04-9 774583-16-3 774583-73-2**
774583-77-6 774583-80-1 774583-81-2
774583-82-3 774583-86-7 774583-87-8
774583-88-9 774583-89-0 774583-90-3
774583-91-4 774583-92-5 774583-93-6
774583-94-7 774583-95-8 774584-02-0
774584-06-4 774584-10-0 774584-12-2
774584-16-6 774584-18-8 774584-22-4
774584-23-5 774584-24-6 774584-25-7
774584-26-8 774584-31-5 774584-32-6
774584-67-7 774585-15-8 774585-48-7
774585-60-3 774585-62-5 1053726-50-3
1053726-51-4 1053726-52-5 1053726-53-6
1053726-56-9 1053726-58-1 1053726-62-7
1053726-63-8 1053726-64-9 1053726-65-0
1053726-68-3 1053726-69-4 1053726-72-9
1053726-77-4 1053726-81-0 1053726-83-2
1053726-84-3 1053726-85-4 1053726-86-5
1053726-90-1 1053726-91-2 1053726-93-4
1053726-96-7 1053726-97-8 1053726-99-0
1053727-00-6 1053727-02-8 1053727-05-1
1053727-07-3 1053727-08-4 1053727-09-5
1053727-12-0 1053727-14-2 1053727-16-4
1053727-17-5 1053727-18-6 1053727-19-7
1053727-21-1 1053727-23-3 1053727-24-4
1053727-26-6 1053727-27-7 1053727-28-8
1053727-29-9 1053727-32-4 1053727-33-5
1053727-36-8 1053727-38-0 1053727-39-1
1053727-40-4 1053727-41-5 1053727-43-7
1053727-44-8 1053727-46-0 1053727-47-1
1053727-48-2 1053727-52-8 1053727-54-0
1053727-57-3 1053727-58-4 1053727-59-5
1053727-61-9 1053727-63-1 1053727-65-3
1053727-72-2 1053727-73-3 1053727-74-4
1053727-77-7 1053727-78-8 1053727-79-9
1053727-82-4 1053727-84-6 1053727-85-7
1053727-86-8 1053727-90-4 1053727-92-6
1053727-93-7 1053727-94-8 1053727-96-0
1053727-98-2 1053727-99-3 1053728-01-0
1053728-03-2 1053728-04-3 1053728-05-4
1053728-07-6 1053728-08-7 1053728-09-8
1053728-11-2 1053728-14-5 1053728-15-6
1053728-16-7 1053728-18-9 1053728-24-7
1053728-27-0 1053728-30-5 1053728-38-3
1053728-39-4 1053728-42-9 1053728-48-5
1053728-49-6 1053728-52-1 1053728-53-2
1053728-54-3 1053728-56-5 1053728-59-8
1053728-60-1 1053728-61-2 1053728-63-4
1053728-65-6 1053728-66-7 1053728-69-0
1053728-71-4 1053728-72-5 1053728-74-7
1053728-78-1 1053728-79-2 1053728-80-5
1053728-81-6 1053728-93-0 1053728-94-1
1053728-96-3 1053728-97-4 1053728-98-5
1053728-99-6 1053729-01-3 1053729-03-5
1053729-05-7 1053729-07-9 1053729-08-0
1053729-12-6 1053729-13-7 1053729-14-8
1053729-16-0 1053729-17-1 1053729-18-2
1053729-20-6 1053729-21-7 1053729-24-0
1053729-28-4 1053729-34-2 1053729-37-5
1053729-39-7 1053729-41-1 1053729-42-2
1053729-43-3 1053729-48-8 1053729-51-3
1053729-58-0 1053729-59-1 1053729-62-6
1053729-74-0 1053729-76-2 1053729-78-4
1053729-81-9 1053729-82-0 1053729-83-1
1053729-86-4 1053729-89-7 1053729-90-0
1053729-92-2 1053729-94-4 1053729-95-5
1053729-98-8 1053729-99-9 1053730-01-0
1053730-02-1 1053730-05-4 1053730-06-5
1053730-08-7 1053730-09-8 1053730-13-4

L35 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1053730-18-9 1053730-20-3 1053730-22-5
1053730-26-9 1053730-27-0 1053730-28-1
1053730-30-5 1053730-32-7 1053730-34-9
1053730-35-0 1053730-37-2 1053730-38-3
1053730-39-4 1053730-40-7 1053730-42-9
1053730-43-0 1053730-44-1 1053730-45-2
1053730-48-5 1053730-49-6 1053730-55-4
1053730-57-6 1053730-59-8 1053730-60-1
1053730-62-3 1053730-66-7 1053730-67-8
1053730-71-4 1053730-72-5 1053730-76-9
1053730-77-0 1053730-82-7
RL: PRPH (Prophetic)
(Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

IT **1053730-84-9 1053730-85-0 1053730-87-2**
1053730-88-3 1053730-89-4 1053730-92-9
1053730-93-0 1053730-94-1 1053730-95-2
1053731-00-2 1053731-02-4 1053731-03-5
1053731-05-7 1053731-13-7 1053731-14-8
1053731-16-0 1053731-18-2 1053731-20-6
1053731-21-7 1053731-25-1 1053731-26-2
1053731-27-3 1053731-29-5 1053731-30-8
1053731-33-1 1053731-35-3 1053731-37-5
1053731-38-6 1053731-39-7 1053731-42-2
1053731-44-4 1053731-45-5 1053731-53-5
1053731-54-6 1053731-57-9 1053731-59-1
1053731-60-4 1053731-61-5 1053731-64-8
1053731-66-0 1053731-67-1 1053731-70-6
1053731-72-8 1053731-74-0 1053731-75-1
1053731-79-5 1053731-81-9 1053731-83-1
1053731-86-4 1053731-88-6 1053731-90-0
1053731-91-1 1053731-92-2 1053731-93-3
1053731-94-4 1053731-96-6 1053731-97-7
1053732-00-5 1053732-03-8 1053732-08-3
1053732-10-7 1053732-12-9 1053732-13-0
1053732-15-2 1053732-16-3 1053732-19-6
1053732-21-0 1053732-24-3 1053732-28-7
1053732-29-8 1053732-33-4 1053732-38-9
1053732-39-0 1053732-43-6 1053732-44-7
1053732-45-8 1053732-46-9 1053732-49-2
1053732-50-5 1053732-51-6 1053732-52-7
1053732-55-0 1053732-56-1 1053732-58-3
1053732-61-8 1053732-63-0 1053732-64-1
1053732-66-3 1053732-67-4 1053732-69-6
1053732-71-0 1053732-73-2 1053732-74-3
1053732-77-6 1053732-78-7 1053732-81-2
1053732-82-3 1053732-84-5 1053732-86-7
1053732-89-0 1053732-90-3 1053733-01-9
1053733-03-1 1053733-05-3 1053733-06-4
1053733-07-5 1053733-08-6 1053733-11-1
1053733-13-3 1053733-14-4 1053733-17-7
1053733-19-9 1053733-20-2 1053733-24-6
1053733-29-1 1053733-35-9 1053733-40-6
1053733-43-9 1053733-45-1 1053733-47-3
1053733-48-4 1053733-52-0 1053733-53-1
1053733-56-4 1053733-59-7 1053733-62-2
1053733-67-7 1053733-69-9 1053733-72-4
1053733-75-7 1053733-82-6 1053733-84-8
1053733-86-0 1053733-88-2 1053733-89-3
1053733-91-7 1053733-93-9 1053733-94-0
1053733-96-2 1053733-97-3 1053733-98-4
1053734-00-1 1053734-02-3 1053734-03-4
1053734-05-6 1053734-08-9 1053734-10-3
1053734-12-5 1053734-13-6 1053734-19-2
1053734-24-9 1053734-26-1 1053734-28-3
1053734-29-4 1053734-31-8 1053734-32-9
1053734-34-1 1053734-35-2 1053734-37-4
1053734-38-5 1053734-41-0 1053734-42-1
1053734-43-2 1053734-44-3 1053734-45-4
1053734-46-5 1053734-49-8 1053734-57-8
1053734-58-9 1053734-59-0 1053734-66-9
1053734-72-7 1053734-74-9 1053734-75-0
1053734-80-7 1053734-83-0 1053734-85-2
1053734-88-5 1053734-89-6 1053734-90-9

L35 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1053734-93-2 1053734-94-3 1053735-01-5
1053735-02-6 1053735-06-0 1053735-08-2
1053735-11-7 1053735-13-9 1053735-16-2
1053735-17-3 1053735-18-4 1053735-19-5
1053735-24-2 1053735-30-0 1053735-32-2
1053735-33-3 1053735-35-5 1053735-36-6
1053735-39-9 1053735-40-2 1053735-41-3
1053735-43-5 1053735-47-9 1053735-48-0
1053735-49-1 1053735-51-5 1053735-55-9
1053735-56-0 1053735-58-2 1053735-59-3
1053735-62-8 1053735-67-3 1053735-73-1
1053735-74-2 1053735-76-4 1053735-80-0
1053735-82-2 1053735-83-3 1053735-84-4
1053735-86-6 1053735-87-7 1053735-88-8
1053735-89-9 1053735-93-5 1053735-94-6
1053735-95-7 1053736-00-7 1053736-02-9
1053736-04-1 1053736-07-4 1053736-08-5
1053736-12-1 1063716-93-7 1063716-96-0
1063716-97-1 1063717-03-2 1063717-41-8
1063717-57-6 1063717-69-0
RL: PRPH (Prophetic)
(Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

IT **1063719-49-3**
RL: PRPH (Prophetic)
(Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

IT **508219-76-9P**, 5-(2-Fluorophenyl)-1-(6-phenylpyridin-3-yl)-1H-pyrazol-4-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

IT **508219-08-7P 508219-09-8P 508219-10-1P**
508219-11-2P 508219-12-3P 508219-13-4P
508219-14-5P 508219-15-6P,
1-Biphenyl-4-yl-4-(2,5-dihydropyrrol-1-ylmethyl)-5-(2-fluorophenyl)-1H-pyrazol **508219-16-7P 508219-17-8P 508219-18-9P**
508219-19-0P 508219-20-3P 508219-21-4P
508219-22-5P 508219-23-6P 508219-24-7P
508219-25-8P 508219-26-9P 508219-27-0P
508219-28-1P, 3-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]acrylic acid **508219-29-2P**,
3-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]acrylic acid ethyl ester **508219-30-5P**, 3-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]prop-2-en-1-ol **508219-31-6P**,
4-[2-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]-ethyl]morpholine
508219-32-7P 508219-33-8P 508219-34-9P
508219-35-0P, 4-[3-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-propynyl]morpholine **508219-36-1P 508219-37-2P**
508219-38-3P 508219-39-4P 508219-40-7P
508219-41-8P 508219-42-9P 508219-43-0P
508219-44-1P, 1-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]-1-(4-methyl-piperazin-1-yl)methanone **508219-45-2P**
508219-46-3P 508219-47-4P 508219-48-5P
508219-49-6P 508219-51-0P 508219-52-1P
508219-53-2P 508219-54-3P 508219-55-4P
508219-56-5P 508219-57-6P 508219-58-7P
508219-59-8P 508219-60-1P 508219-61-2P
508219-62-3P 508219-63-4P 508219-64-5P
508219-65-6P 508219-66-7P 508219-68-9P
508219-69-0P 508219-70-3P 508219-71-4P
508219-72-5P 508219-73-6P 508219-74-7P
508219-75-8P 508219-77-0P,
(5-(2-Fluorophenyl)-1-(6-phenylpyridin-3-yl)-1H-pyrazol-4-yl]methanol
508219-78-1P 508219-79-2P 508219-86-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

IT **508219-82-7 508219-83-8 508219-84-9**
508219-85-0 508219-87-2

L35 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

IT **774583-04-9**
RL: PRPH (Prophetic)
(Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

RN 774583-04-9 HCAPLUS

CN 1H-Pyrazole-4-methanol, 1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)- (CA INDEX NAME)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:49:02 ON 06 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:49:02 ON 06 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:49:02 ON 06 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l48 tot
```

L48 ANSWER 1 OF 2 USPATFULL on STN
AN 2007:12116 USPATFULL
TI Substituted pyrazole compounds
IN **Schadt, Oliver**, Rodenbach, GERMANY, FEDERAL REPUBLIC OF
Arlt, Michael, Alsbach, GERMANY, FEDERAL REPUBLIC OF
Finsinger, Dirk, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Schiemann, Kai, Seeheim-Jugenheim, GERMANY, FEDERAL REPUBLIC OF
Van Amsterdam, Christoph, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Bartoszyk, Gerd, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Seyfried, Christoph, Seeheim-Jugenheim, GERMANY, FEDERAL REPUBLIC OF
PI US-20070010531 A1 20070111
AI 2004US-000552064 A1 20040310 (10)
2004WO-EP0002453 20040310
20051005 PCT 371 date
PRAI 2003DE-010315569 20030405
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1857
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula (I) and salts and solvates thereof, in which X, R.sup.1, R.sup.2, R.sup.3, and R.sup.5 have the meanings indicated in claim 1, are suitable as ligands of 5 HT receptors. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **508219-09-8 508219-31-6 770739-06-5**
770739-07-6 770739-08-7 770739-09-8
770739-10-1 770739-11-2 770739-12-3
770739-13-4 770739-14-5 770739-15-6
770739-16-7 770739-17-8 770739-18-9
770739-19-0 770739-20-3 770739-21-4
770739-22-5 770739-23-6 770739-24-7
770739-25-8 770739-26-9 770739-27-0
770739-28-1 770739-29-2 770739-30-5
770739-31-6 770739-32-7 770739-33-8
770739-34-9 770739-35-0 770739-36-1
770739-37-2 770739-38-3 770739-39-4
770739-40-7 770739-41-8 770739-42-9
770739-43-0 770739-44-1 770739-45-2
770739-46-3 770739-47-4 770739-48-5
770739-49-6 770739-50-9 770739-51-0
770739-52-1 770739-53-2 770739-54-3
770739-55-4 770739-56-5 770739-57-6
770739-59-8 770739-60-1 770739-61-2
770739-63-4 770739-66-7 770739-67-8
770739-68-9 770739-69-0 770739-70-3
770739-71-4 770739-72-5 770739-73-6
770739-74-7 770739-75-8 770739-76-9
770739-77-0 770739-78-1 770739-79-2
770739-80-5 770739-81-6 770739-82-7
770739-83-8 770739-84-9 770739-85-0
770739-86-1 770739-87-2 770739-89-4
770739-90-7 770739-91-8 770739-93-0
770739-94-1 770739-95-2 770739-96-3
770739-97-4 770739-98-5 770739-99-6
770740-00-6 770740-01-7 770740-02-8
770740-03-9 770740-04-0 770740-05-1
770740-06-2 770740-07-3 770740-08-4
770740-09-5 770740-10-8 770740-11-9
770740-12-0 770740-14-2 770740-15-3
770740-16-4 770740-17-5 770740-18-6
770740-19-7 770740-20-0 770740-21-1
770740-22-2 770740-23-3 770740-24-4
770740-25-5 770740-26-6 770740-27-7

L48 ANSWER 1 OF 2 USPATFULL on STN (Continued)
770740-28-8 770740-29-9 770740-30-2
770740-33-5 770740-34-6 770740-35-7
770740-36-8 770740-37-9 770740-38-0
770740-39-1 770740-40-4 770740-41-5
770740-42-6 770740-43-7 770740-44-8
770740-45-9 770740-46-0 770740-47-1
770740-49-3 770740-50-6 770740-52-8
770740-53-9 770740-54-0 770740-55-1
770740-56-2 770740-57-3 770740-59-5
770740-60-8 770740-61-9 770740-62-0
770740-63-1 770740-64-2 770740-65-3
770740-66-4 770740-67-5 770740-68-6
770740-69-7 770740-70-0 770740-71-1
770740-72-2 770740-73-3 771525-15-6
(prepn. of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists)
IT **508219-09-8**
(preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists)
RN 508219-09-8 USPATFULL
CN Piperazine, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]methyl]-4-(phenylmethyl)- (CA INDEX NAME)



L48 ANSWER 2 OF 2 USPATFULL on STN
AN 2006:308806 USPATFULL
TI Substituted pyrazoles
IN **Schiemann, Kai**, Seeheim-Jugenheim, GERMANY, FEDERAL REPUBLIC OF
Ackermann, Karl-August, Ober-Ramstadt, GERMANY, FEDERAL REPUBLIC OF
Arlt, Michael, Alsbach, GERMANY, FEDERAL REPUBLIC OF
Finsinger, Dirk, Munich, GERMANY, FEDERAL REPUBLIC OF
Van Amsterdam, Christoph, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Bartoszyk, Gerd, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Seyfried, Christoph, Seeheim-Jugenheim, GERMANY, FEDERAL REPUBLIC OF
Schadt, Oliver, Rodenbach, GERMANY, FEDERAL REPUBLIC OF
PI US-20060264419 A1 20061123
AI 2004US-000552065 A1 20040308 (10)
2004WO-EP0002353 20040308
20051005 PCT 371 date
PRAI 2003DE-010315572 20030405
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of the formula (I) and salts and solvates thereof, in which X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings indicated in Claim (1), are suitable as ligands of 5 HT receptors. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **508219-08-7P 508219-09-8P 508219-10-1P**
508219-13-4P 508219-14-5P 508219-15-6P
508219-16-7P 508219-17-8P 508219-18-9P
508219-19-0P 508219-20-3P 508219-22-5P
508219-23-6P 508219-24-7P 508219-27-0P
508219-31-6P 508219-32-7P 508219-33-8P
508219-34-9P 508219-35-0P 508219-36-1P
508219-40-7P 508219-42-9P 508219-44-1P
508219-46-3P 508219-47-4P 508219-49-6P
508219-73-6P 508219-86-1P 770739-50-9P
770739-73-6P 770739-84-9P 770739-98-5P
770740-20-0P 770740-35-7P 770740-36-8P
774583-04-9P 774583-05-0P 774583-06-1P
774583-08-3P 774583-16-3P 774583-47-0P
774583-60-7P 774583-61-8P 774583-62-9P
774583-65-2P 774583-73-2P 774583-75-4P
774583-77-6P 774583-80-1P 774583-81-2P
774583-82-3P 774583-84-5P 774583-85-6P
774583-86-7P 774583-87-8P 774583-88-9P
774583-89-0P 774583-90-3P 774583-91-4P
774583-92-5P 774583-93-6P 774583-94-7P
774583-95-8P 774583-96-9P 774584-02-0P
774584-04-2P 774584-06-4P 774584-08-6P
774584-10-0P 774584-12-2P 774584-14-4P
774584-16-6P 774584-17-7P 774584-18-8P
774584-19-9P 774584-20-2P 774584-21-3P
774584-22-4P 774584-23-5P 774584-24-6P
774584-25-7P 774584-26-8P 774584-27-9P
774584-31-5P 774584-32-6P 774584-34-8P
774584-35-9P 774584-36-0P 774584-37-1P
774584-38-2P 774584-40-6P 774584-41-7P
774584-42-8P 774584-43-9P 774584-44-0P
774584-45-1P 774584-47-3P 774584-48-4P
774584-49-5P 774584-50-8P 774584-51-9P
774584-52-0P 774584-61-1P 774584-62-2P
774584-63-3P 774584-64-4P 774584-65-5P
774584-66-6P 774584-67-7P 774584-70-2P
774584-72-4P 774584-73-5P 774584-74-6P
774584-75-7P 774584-76-8P 774584-77-9P
774584-78-0P 774584-79-1P 774584-80-4P
774584-81-5P 774584-82-6P 774584-83-7P

L48 ANSWER 2 OF 2 USPATFULL on STN (Continued)
774584-84-8P 774584-85-9P 774584-88-2P
774584-89-3P 774584-90-6P 774584-91-7P
774584-92-8P 774584-93-9P 774584-94-0P
774584-95-1P 774584-96-2P 774584-97-3P
774584-98-4P 774584-99-5P 774585-00-1P
774585-01-2P 774585-02-3P 774585-03-4P
774585-04-5P 774585-06-7P 774585-09-0P
774585-10-3P 774585-11-4P 774585-12-5P
774585-13-6P 774585-14-7P 774585-15-8P
774585-16-9P 774585-17-0P 774585-18-1P
774585-20-5P 774585-21-6P 774585-24-9P
774585-25-0P 774585-27-2P 774585-28-3P
774585-30-7P 774585-31-8P 774585-33-0P
774585-34-1P 774585-35-2P 774585-36-3P
774585-37-4P 774585-38-5P 774585-39-6P
774585-40-9P 774585-41-0P 774585-42-1P
774585-43-2P 774585-44-3P 774585-45-4P
774585-46-5P 774585-47-6P 774585-48-7P
774585-49-8P 774585-51-2P 774585-52-3P
774585-53-4P 774585-55-6P 774585-56-7P
774585-57-8P 774585-58-9P 774585-59-0P
774585-60-3P 774585-61-4P 774585-62-5P
774585-63-6P 774585-64-7P 774585-66-9P
774585-67-0P 774585-68-1P 774585-69-2P
774585-70-5P 774585-71-6P 774585-73-8P
774585-74-9P 774585-75-0P 774585-76-1P
774585-77-2P 774585-78-3P 774585-80-7P
774585-81-8P 774585-82-9P 774593-64-5P
774593-66-7P 774593-70-3P
(prepn. of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
IT **508219-08-7P**
(preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 508219-08-7 USPATFULL
CN Piperidine, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



```
=> d his


     (FILE 'HOME' ENTERED AT 10:34:52 ON 06 MAR 2009)

     FILE 'HCAPLUS' ENTERED AT 10:35:22 ON 06 MAR 2009
L1             1 US20060276650 /PN

     FILE 'REGISTRY' ENTERED AT 10:35:41 ON 06 MAR 2009

     FILE 'HCAPLUS' ENTERED AT 10:35:41 ON 06 MAR 2009
L2             TRA L1 1- RN :       49 TERMS

     FILE 'REGISTRY' ENTERED AT 10:35:41 ON 06 MAR 2009
L3            49 SEA L2
L4            44 L3 AND N2C3/ES
L5               STR
L6            50 L5
                 E PYRIDINE/CN
L7       1216632 N2C3/ES AND (46.150.18 OR 46.156.30)/RID AND NR>=3
L8            50 L5 SAM SUB=L7
L9               STR L5
L10           50 L9 SAM SUB=L7
L11       106513 L9 FULL SUB=L7
                 SAV TEM J905C1/A L11
L12              STR L9
L13              STR L9
L14           50 (L12 OR L13) SAM SUB=L11
L15         6421 (L12 OR L13) FULL SUB=L11
L16           29 L15 AND L3
L17         6392 L15 NOT L16

     FILE 'HCAPLUS' ENTERED AT 10:52:42 ON 06 MAR 2009
L18            2 L16
                 SEL HIT RN 2

     FILE 'REGISTRY' ENTERED AT 10:53:16 ON 06 MAR 2009
L19            1 E1

     FILE 'HCAPLUS' ENTERED AT 10:54:21 ON 06 MAR 2009
L20            1 L18 AND L1
L21            1 L18 NOT L20
L22          276 L17
L23          138 L22 AND PD<=20030405
L24          115 L22 AND PD<=20020405
L25           55 L22 AND (PRD<=20040308 OR AD<=20040308)
                 SEL HIT RN
                 DEL SEL Y
L26          158 L23-25

     FILE 'REGISTRY' ENTERED AT 11:04:22 ON 06 MAR 2009
L27              TRA L26 1- RN :    56277 TERMS
L28              STR L12
L29              STR L13
L30           50 (L28 OR L29) SAM CSS SUB=L17
L31         1733 (L28 OR L29) FULL CSS SUB=L17
                 SAV TEM J905C1N/A L31

     FILE 'HCAPLUS' ENTERED AT 11:14:46 ON 06 MAR 2009
L32          140 L31
L33          110 L32 AND L26
                 DEL SEL Y
                 SEL HIT RN
                 DEL SEL Y
L34           95 L33 AND L23-24
L35           15 L33 NOT L34
                 SEL HIT RN
                 DEL SEL Y
                 SEL HIT RN L34
```

```
     FILE 'REGISTRY' ENTERED AT 11:17:11 ON 06 MAR 2009
L36         315 E1-315
L37           3 L36 AND (C28H21N2S2 OR C24H20N2O2)
L38           1 L37 AND C24H20N2O2

     FILE 'HCAPLUS' ENTERED AT 11:43:23 ON 06 MAR 2009
L39           2 L38

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:44:57 ON 06 MAR 2009
L40          41 L31
L41           1 L16
                E SCHADT O/AU
L42          24 E4-5
                E SCHIEMANN K/AU
L43          37 E4
                E VAN AMSTERDAM C/AU
L44          41 E4-5
                E BARTOSZYK G/AU
L45          75 E4
                E SEYFRIED C/AU
L46          94 E5-6
L47       10909 MERCK/CS,PA
L48           2 L40-41 AND L42-47

=>
```